GGrantIndex
← Leaderboards

Eugene W. St Clair

Duke University

Google Scholar ↗PubMed ↗ORCID ↗
$30,992,512
Attributed
$30,992,512
Total exposure
13
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $13.9M · FY2005–17
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$66,310,846 · 14

By mechanism

U19$62,231,652 · 3
M01$3,370,670 · 8
K24$432,524 · 1
R34$156,000 · 1
R13$120,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectRheumatoid ArthritisClinical TrialsDrug Screening /EvaluationHuman Therapy EvaluationImmunotherapyAutoimmune DiseasesB-LymphocytesResponseAutoimmunityPlacebosScientistSkeletal Disorder ChemotherapyBasic ScienceDrug Adverse EffectResearch Project GrantsEnzyme ActivityFundingResearch PersonnelNitric Oxide SynthaseArthritis TherapyNitric OxideRheumatology

Grant awards (62)

Autoimmunity Centers of Excellence Discretionary Fund for Clinical Trials$259,859
U19 · FY2017 · AI · contact PI
Mechanisms of B Cell Responses in Autoimmune Disease$259,859
U19 · FY2017 · AI · contact PI
Mechanisms of B Cell Responses in Autoimmune Disease$7,442,164
U19 · FY2013 · AI · contact PI
Autoimmunity Centers of Excellence Discretionary Fund for Clinical Trials$6,351,285
U19 · FY2013 · AI · contact PI
Administrative Core$121,206
U19 · FY2013 · AI · contact PI
Autoimmunity Centers of Excellence Discretionary Fund for Clinical Trials$5,517,910
U19 · FY2012 · AI · contact PI
Mechanisms of B Cell Responses in Autoimmune Disease$5,003,883
U19 · FY2012 · AI · contact PI
Administrative Core$75,685
U19 · FY2012 · AI · contact PI
Mechanisms of Beta Cell Responses in Autoimmune Disease$6,390,755
U19 · FY2011 · AI · contact PI
Discretionary Fund$4,222,621
U19 · FY2011 · AI · contact PI
Administrative Core$623,258
U19 · FY2011 · AI · contact PI
Mechanisms of B Cell Responses in Autoimmune Disease$6,361,642
U19 · FY2010 · AI · contact PI
Discretionary Fund$4,242,735
U19 · FY2010 · AI · contact PI
Administrative Core$626,226
U19 · FY2010 · AI · contact PI
Mechanisms of B Cell Responses in Autoimmune Disease$59,550
U19 · FY2010 · AI · contact PI
Mechanisms of Beta Cell Responses in Autoimmune Disease$6,425,901
U19 · FY2009 · AI · contact PI
Discretionary Fund$4,245,850
U19 · FY2009 · AI · contact PI
Administrative Core$626,683
U19 · FY2009 · AI · contact PI
ACR Basic Research Conference$40,000
R13 · FY2009 · AR · contact PI
ACR Basic Research Conference$40,000
R13 · FY2008 · AR · contact PI
Modulation of B Cell Responses in Autoimmunity$732,285
U19 · FY2007 · AI · contact PI
Abatacept Vs TNF Blockade in Early Rheumatoid Arthritis$156,000
R34 · FY2007 · AR · contact PI
ACR Basic Research Conference$40,000
R13 · FY2007 · AR · contact PI
Modulation of B Cell Responses in Autoimmunity$747,316
U19 · FY2006 · AI · contact PI
Modulation of B Cell Responses in Autoimmunity$760,953
U19 · FY2005 · AI
RITUXIMAB FOR ANCA-ASSOCIATED VASCULITIS$6,799
M01 · FY2005 · RR
ENBREL(TM) IN WEGENER'S GRANULOMATOSIS$3,138
M01 · FY2005 · RR
Modulation of B Cell Responses in Autoimmunity$754,006
U19 · FY2004 · AI
Enbrel(TM) in Wegener's Granulomatosis$16,915
M01 · FY2004 · RR
GENETIC POLYMORPHISMS IN WEGENER'S GRANULOMATOSIS$422
M01 · FY2004 · RR
Modulation of B Cell Responses in Autoimmunity$380,020
U19 · FY2003 · AI
NOVEL THERAPEUTIC TARGETS IN RHEUMATOID ARTHRITIS$107,927
K24 · FY2003 · AR
ANTI TNF ANTIBODY IN RHEUMATOID ARTHRITIS$117,022
M01 · FY2002 · RR
SUBCUTANEOUS RHUIL4 IN PATIENTS WITH RA$117,022
M01 · FY2002 · RR
ANTIBIOTIC THERAPY FOR RHEUMATOID ARTHRITIS (ATRA TRIAL)$117,022
M01 · FY2002 · RR
SUBCUTANEOUS RHUIL10 THERAPY FOR RHEUMATOID ARTHRITIS$117,022
M01 · FY2002 · RR
SULFASALAZINE ON NITRIC OXIDE/CYCLOOXYGENASE PATHWAYS IN RHEUMATOID ARTHRITIS$117,022
M01 · FY2002 · RR
NOVEL THERAPEUTIC TARGETS IN RHEUMATOID ARTHRITIS$107,927
K24 · FY2002 · AR
ANTI TNF ANTIBODY IN RHEUMATOID ARTHRITIS$293,069
M01 · FY2001 · RR
SUBCUTANEOUS RHUIL4 IN PATIENTS WITH RA$293,069
M01 · FY2001 · RR
ANTIBIOTIC THERAPY FOR RHEUMATOID ARTHRITIS (ATRA TRIAL)$293,069
M01 · FY2001 · RR
SUBCUTANEOUS RHUIL10 THERAPY FOR RHEUMATOID ARTHRITIS$293,069
M01 · FY2001 · RR
SULFASALAZINE ON NITRIC OXIDE/CYCLOOXYGENASE PATHWAYS IN RHEUMATOID ARTHRITIS$293,069
M01 · FY2001 · RR
ANTIBIOTIC THERAPY FOR RHEUMATOID ARTHRITIS (ATRA TRIAL)$117,022
M01 · FY2001 · RR
SULFASALAZINE ON NITRIC OXIDE/CYCLOOXYGENASE PATHWAYS IN RHEUMATOID ARTHRITIS$117,022
M01 · FY2001 · RR
SULFASALAZINE ON NITRIC OXIDE/CYCLOOXYGENASE PATHWAYS IN RHEUMATOID ARTHRITIS$117,022
M01 · FY2001 · RR
SUBCUTANEOUS RHUIL10 THERAPY FOR RHEUMATOID ARTHRITIS$117,022
M01 · FY2001 · RR
SUBCUTANEOUS RHUIL10 THERAPY FOR RHEUMATOID ARTHRITIS$117,022
M01 · FY2001 · RR
ANTI TNF ANTIBODY IN RHEUMATOID ARTHRITIS$117,022
M01 · FY2001 · RR
ANTI TNF ANTIBODY IN RHEUMATOID ARTHRITIS$117,022
M01 · FY2001 · RR
SUBCUTANEOUS RHUIL4 IN PATIENTS WITH RA$117,022
M01 · FY2001 · RR
SUBCUTANEOUS RHUIL4 IN PATIENTS WITH RA$117,022
M01 · FY2001 · RR
ANTIBIOTIC THERAPY FOR RHEUMATOID ARTHRITIS (ATRA TRIAL)$117,022
M01 · FY2001 · RR
NOVEL THERAPEUTIC TARGETS IN RHEUMATOID ARTHRITIS$107,927
K24 · FY2001 · AR
NOVEL THERAPEUTIC TARGETS IN RHEUMATOID ARTHRITIS$108,743
K24 · FY2000 · AR
SULFASALAZINE ON NITRIC OXIDE/CYCLOOXYGENASE PATHWAYS IN RHEUMATOID ARTHRITIS$40,907
M01 · FY2000 · RR
SUBCUTANEOUS RHUIL4 IN PATIENTS WITH RA$40,907
M01 · FY2000 · RR
ANTIBIOTIC THERAPY FOR RHEUMATOID ARTHRITIS (ATRA TRIAL)$40,907
M01 · FY2000 · RR
ANTI TNF ANTIBODY IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ANTI TNF ANTIBODY IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
SUBCUTANEOUS RHUIL10 THERAPY FOR RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
SUBCUTANEOUS RHUIL10 THERAPY FOR RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR